Group 1 - The core viewpoint of the articles indicates that despite a decline in performance in the first half of 2025 compared to the same period in 2024, the company shows resilience in its operations, with a slight overall decrease in annual performance compared to 2024 [1] - The number of IVF cycles in the Greater China region is expected to improve, with a reduction in the decline from -5.2% in the first three quarters of 2024 to -1.4% for the entire year of 2025 [1] - The flagship hospital in Chengdu has shown significant improvement, with IVF cycles turning from a decline of -1.9% in the first three quarters of 2025 to a growth of 1.3% for the entire year [1] Group 2 - Looking ahead to 2026 and beyond, the company plans to enhance clinical treatment outcomes, patient care quality, and service supply levels while accelerating the upgrade of core reproductive medical technologies [2] - The company aims to deepen research innovation and clinical translation in reproductive medicine, optimize medical processes, and improve digital service experiences [2] - The company will leverage national fertility support policies and industry development opportunities to strengthen its competitiveness and provide high-quality medical services, ultimately creating long-term stable value for shareholders [2]

下表載列本集團自有醫院和投資－營運－移交（「IOT」）協議或管理服務協議（「MSA」）1 管 理的醫院及診所於截至2025年12月31日止年度及截至2025年9月30日止九個月的IVF取卵 周期數，連同2024年同期的比較數據： Jinxin Fertility Group Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 1951 * 自願公告 2025年第四季度的主要營運數據 本公告乃由錦欣生殖醫療集團有限公司*（「本公司」）自願刊發，旨在使本公司股東及潛在 投資者了解本公司及其附屬公司（「本集團」）的最新業務進展。 本公司董事會（「董事會」）欣然宣佈，通過持續不斷的優化運營措施，於2025年第四季 度，本集團的體外受精（「IVF」）取卵周期數較2025年第三季度有了進一步提升。儘管2025 年上半年業績較2024年同期下滑8.0%，但本集團2025年大中華區業務仍展現出強勁韌 性，全年業績相較2024年僅微降0.4%，已基本回升至 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告的全部或任何部份內容所產生 或因依賴該等內容而引致的任何損失承擔任何責任。 Jinxin Fertility Group Limited 錦 欣 生 殖 醫 療 集 團 有 限 公 司* 委任代理首席財務官 本公告由錦欣生殖醫療集團有限公司*（「本公司」，連同其附屬公司，統稱為「本 集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及 香港法例第571章證券及期貨條例第XIVA部項下內幕消息條文（定義見上市規則） 刊發。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資 者，根據對本集團截至二零二五年六月三十日止六個月（「二零二五年上半年」） 的未經審核綜合管理賬目（按照國際財務報告準則編製）的初步評估及董事會 目前可得資料，預期本集團將於二零二五年上半年錄得虧損不超過人民幣1,090 百萬元，而本集團於截至二零二四年六月三十日止六個月（「二零二四年上半年」） 則錄得純利約人民幣190百萬元。此虧損乃主要由於就有關本集團 ...

Group 1 - The Federal Reserve has maintained interest rates for the fifth consecutive time, leading to mixed performance in the U.S. stock market, with major indices showing varied results [1] - The Chinese concept index fell by 1.82%, while Hong Kong's three major indices opened lower, with the Hang Seng Index down by 0.77% and the Hang Seng Tech Index down by 0.58% [1] - Major technology stocks in Hong Kong continued to decline, with Meituan dropping by 3%, and JD, Alibaba, and Xiaomi each falling by approximately 1% [1] Group 2 - Innovative drug concept stocks experienced a pullback, with WuXi AppTec planning to issue 73.8 million H-shares at a discount of 6.9% to raise HKD 7.7 billion, resulting in a 4% drop in its stock price [1] - Gold prices fell over 1.7% in New York, with the Philadelphia Gold and Silver Index declining by more than 3.3%, leading to a general downturn in gold stocks, including China Silver Group and Lingbao Gold, which both fell by over 3% [1] - Chinese brokerage and insurance stocks mostly declined, with Everbright Securities and China Pacific Insurance both dropping by over 2% [1] Group 3 - The announcement of a 3,600 yuan childbirth subsidy has led to a continued rise in three-child concept stocks, with Jinxin Fertility rising by 3.4% [1] - Some live-streaming and rare earth concept stocks saw partial increases amid the ongoing market developments [1]